Investors

Overview

Webcast ImageWebcast
CTI BioPharma Corp at Piper Jaffray Healthcare Conference  (Live)
12/03/14 at 9:00 a.m. ET
Webcast ImageWebcast
CTI BioPharma Corp at Jefferies Global Heatlhcare Conference - London (Replay)
11/19/14 at 9:20 a.m. GMT

CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$2.22 + 0.05 (2.30%)
Day High:$2.23
Day Low:$2.17
Volume:1,540,074
11/21/144:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345
invest@ctiseattle.com


CTI Life Sciences Limited, Milan Branch
Laura Villa
T +1 39 02 94751572
T +1 206-272-4155 (U.S. only)
LVilla@cti-lifesciences.com
 

Recent News

MORE
DateTitle 
Nov 17, 2014CTI BioPharma to Present at the Upcoming Investor Conferences
SEATTLE, Nov. 17, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) announced today management will present at the following upcoming investor conferences. Jefferies 2014 Global Healthcare Conference Wednesday, November 19 at 9:20 a.m. GMT / 4:20 a.m. EST, London, England. Piper Jaffray 26th Annual Healthcare Conference Wednesday, December 3 at 9:00 a.m. EST, New York, NY. The presentation will also be webcast live and available for replay after the presentation. ... 
Printer Friendly Version
Nov 07, 2014CTI BioPharma Prices Underwritten Public Offering of $35 Million of Convertible Preferred Stock
SEATTLE, Nov. 7, 2014 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 35,000 shares of its Series 21 Preferred Stock, offered at a price to the public of $1,000 per share of Series 21 Preferred Stock (the "Offering"). Each share of Series 21 Preferred Stock is convertible at the option of the holder, at any time, into 500 shares of common stock at a conversion price of $2.00 per share of common stock, for a tota... 
Printer Friendly Version
Nov 06, 2014CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
SEATTLE, Nov. 6, 2014 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series 21 Preferred Stock in an underwritten public offering(the "Offering"). Each share of Series 21 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion ... 
Printer Friendly Version

Events

MORE
DateTitle
Nov 19, 2014
CTI BioPharma Corp at Jefferies Global Heatlhcare Conference - London
Oct 29, 2014
Q3 2014 CTI BioPharma Corp Earnings Conference Call
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.